( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled ...

Phase transformations—in which a material changes from one crystal structure to another, thereby acquiring dramatically ...

Tvardi Therapeutics TVRD stock has skyrocketed 148.8% so far this week, reflecting strong investor enthusiasm following a ...

Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...

ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...

A newly found chain-reaction phase change in 2D MoTe2 lowers energy barriers, enabling faster control of electronic and ...

Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein ...

Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with ...

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...

A deep reinforcement learning framework optimizes silicon-based photonic crystal fiber modulators, achieving ultra-low ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...